Phase II Study Of Single-Agent SU011248 In The Treatment Of Patients With Renal Cell Carcinoma
收藏DataCite Commons2024-12-02 更新2024-07-13 收录
下载链接：
https://search.vivli.org/doiLanding/studies/00006802/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
To determine the objective tumor response of single-agent SU011248 at a dose of 50 mg orally
once daily for 4 consecutive weeks and 2 weeks rest, repeated every 6 weeks in patients with
metastatic Renal Cell Cancer (RCC).
提供机构：
Vivli
创建时间：
2021-04-02
